

Metabolism and Excretion of Canagliflozin in Mice, Rats, Dogs and Humans

Rao N.V.S. Mamidi, Filip Cuyckens, Jie Chen, Ellen Scheers, Dennis Kalamaridis,
Ronghui Lin, Jose Silva, Sue Sha, David C. Evans, Michael F. Kelley,
Damayanthi Devineni, Mark D. Johnson, and Heng Keang Lim

Janssen Research & Development, LLC, Raritan, New Jersey, USA (RNVSM, SS, DD, MDJ)

Janssen Research & Development, LLC, Spring House, Pennsylvania, USA (JC, DK, RL, JS,
DCE, MFK, HKL)

Janssen Research & Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
(FC, ES)

Running Title: In Vivo Metabolism of Canagliflozin in Animals and Humans

Corresponding Author: Rao N. V. S. Mamidi, Ph.D.

Janssen Research & Development, LLC

1000 US Route 202, Raritan, NJ 08869

Telephone: 908-704-4262

Fax: 908-927-7172

Email: smamidi1@its.jnj.com

Number of:

Text pages: 27

Tables: 7

Figures: 10

References: 16

Number of words

Abstract: 249

Introduction: 332

Discussion: 1229

Nonstandard abbreviations:

BDC, bile duct-cannulated; SGLT2, sodium glucose co-transporter 2; canagliflozin, [(1S)-1, 5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol]; TR, total radioactivity; Sv, Sievert; LC, liquid chromatography; HPLC, high-performance liquid chromatography; UHPLC, ultrahigh-performance liquid chromatography; LSC, liquid scintillation counting; C_{\max} , maximum plasma concentration; T_{\max} , time to reach the maximum plasma concentration; AUC, area under the plasma concentration-time curve; MS/MS, tandem mass spectrometry; MS, mass spectrometry; RDB, rings plus double bonds; ppm, parts per million

Abstract

Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes mellitus that blocks the reabsorption of glucose in the proximal renal tubule by inhibiting the sodium-glucose co-transporter 2. This article describes the in vivo biotransformation and disposition of canagliflozin after a single oral dose of [¹⁴C]canagliflozin to intact and bile duct-cannulated (BDC) mice and rats, and to intact dogs and humans. Fecal excretion was the primary route of elimination of drug-derived radioactivity in animals and humans. In BDC mice and rats, the majority of radioactivity was excreted in bile. The extent of radioactivity excreted in urine as a percentage of the administered [¹⁴C]canagliflozin dose was 1.2 to 7.6% in animals and approximately 33% in humans. The primary pathways contributing to the metabolic clearance of canagliflozin were oxidation in animals, and direct glucuronidation of canagliflozin in humans. Unchanged canagliflozin was the major component in systemic circulation in all species. In human plasma, 2 pharmacologically inactive *O*-glucuronide conjugates of canagliflozin, M5 and M7, represented 19 and 14% of total drug-related exposure and were considered as major human metabolites. Plasma concentrations of M5 and M7 in mice and rats from repeated dose safety studies were lower than those in humans given canagliflozin at the maximum recommended dose of 300 mg. However, biliary metabolite profiling in rodents indicated that mouse and rat liver had significant exposure to M5 and M7. Pharmacological inactivity and high water solubility of M5 and M7 support glucuronidation of canagliflozin as a safe detoxification pathway.

Introduction

Type 2 diabetes mellitus (T2DM), a chronic disease with worldwide prevalence (Chen et al., 2011), is characterized by hyperglycemia caused by excessive hepatic glucose production, a deficiency in insulin secretion, and/or peripheral insulin resistance. Drugs for T2DM act by increasing insulin levels, enhancing insulin sensitivity, or reducing glucose absorption. Despite an armamentarium of agents with antihyperglycemic efficacy in T2DM, only 50% of patients achieve glycemic treatment goals set forth by expert societies (Stark Casagrande et al., 2013). Thus, there is a need to develop new agents with novel mechanisms of action to control glucose levels in patients with T2DM. The most desirable drugs would improve glycemic control with little or no risk of hypoglycemia, promote weight loss, and improve pancreatic β -cell function.

SGLT2, a transporter, is expressed primarily in the early proximal renal tubule and is responsible for most of the glucose reabsorption in the kidney (Wright et al., 2007). Inhibition of SGLT2 decreases glucose reabsorption in the renal tubule and increases glucose excretion (Hardman and Dubrey, 2011). Partitioning of glucose out of the body through increased urinary glucose excretion directly reduces elevated blood glucose concentrations. Due to urinary caloric loss secondary to glucose excretion, body weight neutrality or weight loss is expected with SGLT2 inhibitor treatment.

Canagliflozin [CAS#: 842133-18-0, (1*S*)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol], a new oral antihyperglycemic agent and a selective SGLT2 inhibitor, has been shown to reduce the renal threshold for glucose reabsorption, increase urinary glucose excretion, reduce plasma glucose, and promote weight loss in preclinical and clinical studies (Devineni et al., 2013; Liang et al., 2012; Nomura et al., 2010; Rosenstock et al., 2012; Sha et al., 2011).

The objective of the present study was to determine the metabolism and excretion of canagliflozin in preclinical species (mice, rats, and dogs) and humans after a single oral dose of [^{14}C]canagliflozin. Major and minor metabolites were quantified in plasma, urine and feces, and in mouse and rat bile. Information generated from these studies was used to support the nonclinical safety evaluation of canagliflozin.

Materials and Methods

Test article.

Canagliflozin, specifically labeled with ^{14}C at the methylene carbon (Fig. 1), was synthesized by Janssen Research & Development, LLC (Spring House, USA). The ^{14}C label at this position is metabolically stable, as evidenced by the lack of $^{14}\text{CO}_2$ exhalation in the rat after oral dosing of [^{14}C]canagliflozin. The stock solution of [^{14}C]canagliflozin had a specific activity of 2.0 GBq/mmol (4.5 MBq/mg) and a radiochemical purity of 99.8%. Dosing formulations were prepared by combining appropriate amounts of radiolabeled and unlabeled canagliflozin to meet the target specific activity. Radiochemical purities of [^{14}C]canagliflozin in study formulations ranged between 97.2 and 99.8%. Metabolite reference standards were synthesized at Janssen Pharmaceutical Research & Development.

Animal experiments.

All animal experiments were conducted according to the standards recommended by the *Guide for the Care and Use of Laboratory Animals* (Institute of Laboratory Animal Resources, 1996), and protocols were approved by the Janssen Research & Development, LLC Animal Care and Use Committee. All animals were treated with a single dose of [^{14}C]canagliflozin followed by collection of plasma, urine, and feces at predefined intervals (see individual studies below). Mass balance of total radioactivity (TR) for excreta was determined by summing radioactivity in samples for the entire collection period, plus radioactivity in cage debris and cage washings

obtained at terminal sample times. Biliary excretion studies were conducted in bile-duct cannulated (BDC) mice and rats.

Intact mouse study.

Male and female Swiss SPF Albino (CD1) mice obtained from Charles River Laboratories, Inc. (Sulzfeld, Germany) were divided into 2 groups. Group A animals were used for generating plasma metabolite profiles and were housed by sex in grid-bottomed polypropylene cages (N=40/sex; 10 per cage). Those in Group B were used for the metabolism-excretion balance study and were placed in glass metabolism cages (N=16/sex; 4 per cage). A suspension of [¹⁴C]canagliflozin in 0.5% hypromellose with a specific activity of 22.2 kBq/mg was given by oral gavage to 5-week old mice at 100 mg/kg (2.2 MBq/kg). After the dose, plasma samples were collected from Group A animals (N=10/sampling time/sex) at 1, 4, 7 and 24 h, and for Group B animals, urine was collected at defined intervals of 0-7, 7-24, 24-48, 48-72, and 72-96 h, and feces were collected every 24 h for 4 days. All samples were stored at -20° C until analysis.

Intact rat study.

Sprague-Dawley rats of either sex were obtained from Charles River Laboratories, Inc. (Wilmington, MA) at approximately 8-10 weeks of age and were divided into 2 groups. Group A animals were used for generating plasma metabolite profiles and were housed by sex in plastic cages (N=10/sex; 2 per cage), and Group B animals, used for mass balance and metabolic profiling, were placed in metabolic cages (treated, N=4/sex, 1 per cage; vehicle control N=1/sex). [¹⁴C]Canagliflozin was formulated as a suspension in 0.5% hypromellose with a specific activity of 1.5 MBq/mg. Rats were given an oral gavage dose of 3 mg/kg (approximately 4.6 MBq/kg). After dose administration, plasma samples were collected from Group A animals (N=2/sampling time/sex) at 1, 2, 4, 8, and 24 h. For Group B animals, urine

was collected during intervals of 0-4, 4-8, 8-24, 24-48, 48-72, 72-96 and 96-120 h, and feces were collected daily for 5 days. All samples were stored at -20°C until analysis.

Intact dog study.

[¹⁴C]Canagliflozin was formulated as a 0.5% hypromellose suspension at a specific activity of 103 kBq/mg. After an acclimatization period, 3 male dogs obtained from Covance (Cumberland, VA) received an oral gavage dose of [¹⁴C]canagliflozin at 4 mg/kg (approximately 0.4 MBq/kg). Postdose sample collections were obtained at 0.5, 1, 4, 8, 24, 72, and 96 h for plasma, at several intervals between 0 to 144 hours for urine, and on 6 consecutive days for feces. All samples were stored at -20° C until analysis.

BDC mouse study.

Biliary excretion of radioactivity, and canagliflozin metabolites in bile were studied in BDC male CD-1 mice obtained from Charles River, Inc. (Raleigh, NC) at approximately 8-10 weeks of age. Five BDC mice (weighing approximately ~30 g) were housed individually in plastic metabolism cages. Mice fasted overnight received [¹⁴C]canagliflozin as a 0.5% hypromellose suspension with a specific activity of 62 kBq/mg. After a single oral gavage dose of 100 mg/kg (approximately 6.16 MBq/kg), the mice were afforded unlimited access to food water. Bile was collected at intervals from 0-4, 4-8, 8-24 h after the dose. A single pool for each time interval was prepared by mixing common fractions from each mouse. A 0-24 h bile pool was created for each mouse by proportional pooling of samples from the 3 single time-interval pools. Feces were not collected in this study. All bile samples were stored at -20° C until analysis.

BDC rat study.

Biliary excretion of canagliflozin and its metabolites was investigated in BDC male Sprague-Dawley rats obtained from Harlan Laboratories (Netherlands) at approximately 9-11 weeks of age. BDC rats were individually housed in plastic metabolism cages. A single oral dose of [¹⁴C]canagliflozin, formulated as a 0.5% hypromellose suspension with a specific activity of 493 kBq/mg, was administered to 4 rats by oral gavage at a dose level of 3 mg/kg (1.48 MBq/kg). During sample collection, bile salts were replenished with a solution of 0.5% (w/v) sodium taurocholate in 0.9% NaCl infused at 0.6 ml/h via the duodenal catheter. Following dose administration, bile was collected at intervals from 0-4, 4-8, 8-12, 12-16, 16-24 h, and urine and feces were collected over a 0 to 24 h period. Single bile pools for each time interval were created by proportional mixing of samples from each rat. All samples were stored at -20°C until analysis. Representative rat bile samples (0-8 h interval post-dose) were incubated in vitro with β-glucuronidase/arylsulfatase from *Helix pomatia* (Roche Applied Science, Indianapolis, IN) to facilitate identification of glucuronide conjugates of canagliflozin and/or its metabolites. Enzyme treated and untreated bile samples were analyzed by UPLC with radioactivity detection. Mono-oxygenated and *O*-glucuronide metabolites of canagliflozin were identified from product ion spectra generated by an LTQ-Orbitrap mass spectrometer.

Human study.

The metabolism and excretion of canagliflozin was conducted as a single-dose, single-center, open-label study in healthy adult males. The protocol of the clinical trial was approved by an internal review committee and an independent ethics committee, and the trial was performed in accordance with the Declaration of Helsinki (1964) and its subsequent revisions. Six healthy male subjects with the following profile participated in the study: age 19 to 45 years; body mass

index between 18 to 26 kg/m², body weight from 62 to 87 kg, and good health based on medical history. All subjects gave their full informed consent before the start of the study.

A target radioactivity level of 1480 kBq (or 40 µCi) for the intended [¹⁴C]canagliflozin dose was considered sufficient to accurately detect and study canagliflozin metabolism. Human radiation exposure from 1480 kBq of internal ¹⁴C was estimated to be less than 1 mSv. These dosimetry calculations were derived from tissue distribution of total radioactivity in a single-dose [¹⁴C]canagliflozin study in male Long-Evans rats, and from [¹⁴C]canagliflozin excretion-mass balance data in rats and dogs. Radiation doses between 100 and 1000 µSv are classified as category IIa, defined as a minor level of risk to the subject (Verbruggen et al., 2008).

Subjects were admitted to the investigator's facility on Day -1 and fasted overnight for at least 8 hours. [¹⁴C]Canagliflozin was formulated as a 0.5% hypromellose suspension with a specific activity of 7.72 kBq/mg. On Day 1, each subject received a single 188 mg [¹⁴C]canagliflozin dose by orally consuming 4 ml of formulation containing approximately 1451 kBq (39.2 µCi) of radioactivity. Subjects then drank the water (approximately 240 mL) used to rinse drug residue from the medication bottle. Standardized lunch and dinner were provided approximately 4 hours and 10 hours after drug administration, and a snack was allowed in the evening throughout the confinement period. After dose administration, blood samples were obtained at 1.5, 4, 8, 12 and 24 h, urine was collected at intervals of 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 h, and feces (per stool) were collected every 24 h through Day 8. For subjects who had to extend their residency in the study unit, feces were collected for each 24-hour interval. Plasma, urine, and feces were kept at -20°C until sample analysis.

Analysis of radioactivity.

Radioactivity in plasma, urine and bile samples from animal studies was quantified by liquid scintillation counting (LSC) using a Packard 3100TR liquid scintillation counter (PerkinElmer, Shelton, CT). Aliquots of plasma (0.2 mL), urine (0.2 mL), and bile (0.05 mL) were mixed with 15 mL of Ultima Gold scintillation fluid (PerkinElmer, Shelton, CT) and analyzed directly by LSC. Feces from animals and humans were processed as described below and samples were subsequently combusted in a Packard sample oxidizer (A307). Rat and dog fecal samples were homogenized in methanol/water (50/50, v/v) and aliquots were added directly to the sample oxidizer. Mouse and human feces samples were homogenized in methanol followed by centrifugation of the suspension. Residues were extracted twice more with methanol. Residues were suspended in methanol and then recovered by filtration through a Buchner funnel. Radioactivity levels in methanol retained during residue extractions were determined by LSC. Fecal residues were air-dried and then ground to a fine powder in an Ultra Centrifugal Mill ZM100 (Resch GmbH, Haan, Germany). Four weighed portions of each residue sample were placed in the sample oxidizer. Liberated $^{14}\text{CO}_2$ was captured with Carbo-Sorb E (Packard), Permafluor scintillation cocktail was then added, and radioactivity was quantified using a Packard 2900TR or 3100TR liquid scintillation counter (PerkinElmer, Shelton, CT). Rat and dog feces homogenates, and methanol fractions from mouse and human fecal extractions were stored at -20°C until analysis.

Preparation of biological samples for metabolite profiling.

When appropriate, individual or overall pools of urine, bile, or methanolic fecal extracts were prepared by mixing constant fractions of individual samples or individual pools, respectively. Overall plasma pools were prepared by mixing equal volumes of individual samples. For plasma and urine samples, protein was precipitated with 6 volumes of acetonitrile. Methanol from mouse

and human fecal extractions was evaporated to dryness under nitrogen at room temperature prior to protein precipitation with 6 volumes of acetonitrile containing 0.01% formic acid. Protein in 2 g portions of rat and dog feces homogenates was precipitated with 4 to 6 volumes of acetonitrile containing 0.01% formic acid. Acetonitrile extracts of matrices were vortex-mixed and centrifuged at 3000 rpm at 5°C for 10 minutes. At least 85% of radioactivity was recovered in the supernatants of fecal samples. Supernatants of all matrices were evaporated to dryness under a stream of nitrogen and residues were reconstituted in 0.25 mL to 0.5 mL of water:acetonitrile (9:1). Drug-derived materials were solubilized by sonication and vortex-mixing prior to centrifuge filtration of samples through a 0.45 µm nylon filter. Filtrates were transferred to 96-well plates for analysis of metabolites by liquid chromatography and tandem mass spectrometry.

Liquid chromatography.

Except for rat bile, profiling of metabolites in radioactive samples was conducted with an HP 1100 HPLC system (Agilent Technologies, Wilmington, DE) consisting of a solvent delivery pump, membrane degasser, autosampler, and a v.ARC radioactivity detector (AIM Research Company, Hockessin, DE). Chromatographic separation of the unchanged drug and its metabolites was achieved using a HyPurity Aquastar reverse-phase HPLC column (150 × 2.1 mm ID, 3 µm; Thermo Fisher Scientific Inc., Bellefonte, PA) kept at 50°C. A flow rate of 0.4 mL/min was used throughout the analysis. Sample components were eluted with a nonlinear solvent gradient consisting of 2.5 mM ammonium acetate (solvent A) and acetonitrile (solvent B). The mobile phase composition started with 10% B and was increased to 95% B over the course of 35 minutes. The column was then equilibrated for 10 minutes with 10% A. The eluate from the HPLC column was split postcolumn into 2 flows, each directed at a rate of 0.2 mL/min

into the radioactivity detector and the mass spectrometer. The radioactivity detector was operated in the homogenous liquid scintillation dynamic flow counting mode with the addition of 0.2 mL/min of StopFlow™ AD scintillation cocktail (AIM Research Company, Hockessin, DE) to the eluate and mix prior to radioactivity detection.

Rat bile samples were analyzed using Accela (Thermo Fisher Scientific, San Jose, CA, USA) or Acquity/Binary Solvent Manager (Waters Corp., Milford, MA USA) UHPLC systems equipped with an Uptisphere Strategy RPX C-18-2 column (150 x 3 mm ID, 2.2 μm) (Interchim, Montlucon, France) and coupled to a Berthold LB-509 radioactivity detector (Berthold Technologies, Bad Wildbad, Germany). Samples were eluted at a flow rate of 0.8 mL/min with a linear solvent gradient consisting of 2.5 mM ammonium acetate (solvent A) and acetonitrile (solvent B). The eluate from the UHPLC system was split postcolumn into 2 flows, 0.65 mL/min into the radioactivity detector, and 0.15 mL/min into the mass spectrometer. Ultima Flo M scintillation cocktail (Perkin Elmer, Boston, MA, USA) was added with a Berthold scintillator pump via a custom-made variable scintillation flow setup (Cuyckens, et al., 2008). The mobile phase composition started with 10% solvent B and was increased to 90% solvent B over the course of 33 minutes. The column was then equilibrated for 6 minutes using initial mobile phase conditions.

Mass/NMR spectrometry.

LTQ linear ion trap and LTQ-Orbitrap mass spectrometers (Thermo Scientific, Inc.) were used for metabolite identification. Both systems were equipped with an electrospray ionization source operated in the positive ion mode. Accurate mass measurements using LTQ/Orbitrap were obtained by modification of a previously reported procedure for external mass calibration using a mixture of caffeine, MRFA peptide, and Ultramark 1621 (Ultramark Adhesive Products Ltd,

Lancaster, UK) (Lim et al., 2007), or internal mass calibration by infusion of 10 pg/ μ L of tamoxifen (Lim et al., 2011). The source parameters were tuned for maximum sensitivity by infusion of 5 or 10 ng/ μ L canagliflozin in 50% acetonitrile/50% water directly into the mobile phase. The same solution was used to define the optimal collision energy employed during MSⁿ fragmentation. The unchanged drug and its metabolites were detected using data-dependent multiple-stage mass analysis with an isolation width of 2 Da, normalized collision energy of 20, 25, and 30% for MS², MS³ and MS⁴, respectively, an activation *q* of 0.25, and an activation time of 30 msec. Data acquisition and processing was carried out using Xcalibur 2.0 (Thermo Scientific, Inc., San Jose, CA). For a selection of samples, Metabolyx software (Waters, Manchester, UK) was used for metabolite identification via control-analyte comparison after conversion of the XCalibur data.

NMR spectroscopy was used for structural elucidation of selected metabolites (see Supplemental Method).

In vitro pharmacological activities for canagliflozin and its metabolites, M5 and M7.

The canagliflozin *O*-glucuronide metabolites M5 and M7 were assessed for potential inhibitory effects on uptake of the SGLT2 substrate alpha-methyl-D-glucopyranoside in CHO K1 cells stably expressing human SGLT2. M5 and M7 were each evaluated in separate experiments, and canagliflozin was included as the reference. Compounds were prepared in assay medium consisting of 50 mM HEPES, 20 mM Tris base, 5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂ and 137 mM NaCl, pH 7.4. The tested concentration ranges were 0.45-3,000 nM for canagliflozin, 1-5,000 nM for M5, and 12-10,000 nM for M7. Lysine-coated, 96-well plates were seeded with 30,000 or 65,000 cells per well and incubated in growth medium for up to 48 hours. Cells were rinsed with assay medium and then incubated with test compound solutions. After 15 minutes,

0.1 μCi of 500 μM [^{14}C]alpha-methyl-D-glucopyranoside was added to each well and plates were incubated for 2 h at 37°C. Cells were washed at least 3 times with ice-cold phosphate buffer solution and then solubilized by adding 0.05 mL per well of MicroScint-20 (PerkinElmer, Shelton, CT) prior to assay of radioactivity uptake by LSC.

Data Analysis.

The radioactivity excreted in urine and feces was expressed as percentage of the administered radioactivity. The mass balance of canagliflozin and its metabolites was based on total recovery of radioactivity in urine and feces plus collected residual material. Profiles of the plasma concentrations of radioactivity and canagliflozin or its metabolites were analyzed by standard noncompartmental analysis (WinNonlin v4.0.1; Pharsight, Mountainview, CA). At a minimum the following parameters were estimated: maximum plasma concentration (C_{max}) and corresponding peak time (T_{max}), and the area under the plasma concentration-time curve (AUC).

Results

Excretion of Radioactive Dose.

The recovery of radioactivity in urine, feces, or bile was determined after a single oral dose administration of [^{14}C]canagliflozin to either intact mice, rats, dogs, and humans, or BDC mice and BDC rats (Table 1). The majority of the radioactive dose administered to intact animals and humans was excreted in feces, with mean radioactivity recoveries of approximately 92% (0-96 h) in mice, 89-90% (0-120 h) in rats, 94% (0-144 h) in dogs, and 60% (0-168 h) in humans. The radioactivity in fecal samples from mice and humans was calculated as the sum of the radioactivity in the methanol extracts and the fecal residues prepared from these samples. Mean percentages of radioactivity in urine during the same intervals in intact animals were approximately 6% in mice, 4-5% in rats, 2% in dogs, and 33% in humans. The mean recovery of the total radioactivity in bile during a 24-hour collection interval accounted for approximately

49% of the dose in BDC mice and 52% in BDC rats. In BDC rats, the total radioactivity in feces represented approximately 22% of the dose, whereas a smaller amount (~4%) was found in urine. Total recovery of radioactivity ranged from approximately 97 to 99% in intact animals, and 93% in humans.

Pharmacokinetics of Total Radioactivity.

Mean pharmacokinetic parameters of plasma radioactivity in mice, rats, dogs and humans are summarized in Table 2. Plasma radioactivity T_{\max} values ranged between 1 to 8 h, and were lowest in dogs and humans. Plasma radioactivity exposures based on C_{\max} and AUC values were highest in mice and lowest in rats.

Metabolite Profiles in Plasma.

The recovery of radioactivity in pooled plasma samples from animals and humans after solvent extraction ranged from 82 to 92%. Canagliflozin and metabolites were identified in 0-24 h pooled plasma samples from animals and humans (Table 3). For animals, overall plasma pools were used due to limited sample volumes from individual time points. To facilitate species comparison, human plasma values were derived from radiochromatograms and generated by Hamilton pooling of the pooled individual time point plasma samples (Hamilton et al., 1981). The proportion of plasma TR attributed to canagliflozin was 94 to 99% in animals, and 62% in humans. M5 and M7, direct *O*-glucuronide metabolites of canagliflozin, and M9, hydroxylated canagliflozin, represented ~19, 14, and 3% of human plasma TR, respectively. M7 and M9 in mouse plasma accounted for $\leq 3\%$ of TR. No circulatory metabolites were detected in rat and dog. M5 was not detected in animal plasma at the administered [^{14}C]canagliflozin doses used in these studies. Radiochromatograms with metabolite peaks in mouse and human plasma are shown in Fig. 2.

In the human study, blood samples were taken from 1.5 to 24 h after [¹⁴C]canagliflozin administration, and plasma pools were created for each time point. As shown in Fig. 3, total radioactivity and canagliflozin were slowly eliminated from plasma during the entire sampling period. Concentrations of M5, M7 and M9 were maximal at 4 hours, and the M5 level declined markedly after 8 h. None of these metabolites were detectable at 24 h.

The human plasma concentration-time data was used to calculate systemic exposure for TR, canagliflozin, and its metabolites (Table 4). Relative to TR, unchanged drug is the major circulating component. Systemic exposures for M5 and M7 exceeded 10% of TR and are thus considered major human circulating metabolites. M9 can be classified as a minor human metabolite because its systemic exposure was only 2% of TR.

Metabolite Profiles in Urine.

As summarized in Table 5, urinary excretion was a minor elimination pathway for canagliflozin and metabolites in mice, rats, dogs, and humans. Representative radiochromatograms are shown in Fig. 4. Unchanged drug represented anywhere from 0.2 to 0.3% of the administered dose in animals. The only components detected in human urine were M5 and M7, representing 14 and 18% of the administered radioactive dose. The amount of M5 and M7 excreted in mouse urine was low, but these metabolites were not detected in rat and dog urine. Urinary metabolites representing <5% of the dose included *O*-glucuronides of monooxygenated unchanged drug (M1, M2) in mice, a dioxygenated metabolite (M4) in mice and dogs, a carboxy metabolite (M6) in rats, and hydroxylated metabolites (M8, M9) in mice, rats, and dogs.

Metabolite Profiles in Feces.

Overall pools of fecal methanol-water extracts created from samples collected during the first 2 or 3 days represented at least 95% of the radioactivity recovered during the entire collection

period. Representative radiochromatograms of fecal samples from mice, rats, dogs and humans after oral administration of [¹⁴C]canagliflozin are shown in Fig. 5. As shown in Table 6, fecal excretion was the primary elimination route of canagliflozin and its metabolites in animals. Canagliflozin accounted for 3.5 to 11% of the administered radioactivity dose in feces from female mice, rats, and dogs, and 33% of the dose in male mice. Metabolite M8 was most abundant in rat and dog feces, accounting for 42 to 59% of the dose, and M9 was most abundant in mouse feces representing 28 to 29% of the dose. M7 was a fecal metabolite in male and female mice, and dogs, where it represented, respectively, 6 and 14%, and 7% of the dose. Other fecal metabolites were M1 in rat, M4 in mouse and dog, M5 in mouse, M6 in mice and rats, and M10 in rat. In human feces, unchanged drug was the major component, representing 39% of the dose, and M7 and M9 occurred as minor metabolites at 2 and 8% of the dose.

Metabolite Profiles in Bile.

Distribution of metabolites of pooled bile samples from mice and rats are shown in Table 6.

In BDC mice administered 100 mg/kg of [¹⁴C]canagliflozin, M7 was the major biliary metabolite identified in the 0-24 h bile pool, representing 37% of the administered dose. Unchanged drug and M8 accounted for 4 and 7% of the administered dose. M1 and M2 were only detected by mass spectrometry.

In 24-hour bile collections from rats that received a single dose of 3 mg/kg [¹⁴C]canagliflozin, the predominant metabolites in bile, each accounting for ~4 to 12% of the administered dose, were M5, M6, M7, and M8. Less prominent metabolites (<3% of administered dose) included the *O*-glucuronide M5B, oxidative metabolites M12, M18 and M19, and oxidative metabolites that underwent glucuronidation (M1, M13, M14, M15, M16). Unchanged drug accounted for approximately 2% of the dose. Rat bile collected over an 8-hour period was left untreated or

mixed with β -glucuronidase/arylsulfatase in vitro to determine metabolites susceptible to enzymatic hydrolysis. Radiochromatogram peaks corresponding to *O*-glucuronide metabolites M1, M5, M5B, M7, M13, and M14 in untreated bile samples (Fig. 6A) disappeared in the enzyme treated bile samples, while peak areas increased for the aglycones corresponding to canagliflozin, M8, and M18 (Fig. 6B). These results suggest that M1, M5, M5B, M7, M13, and M14 are *O*-glucuronide metabolites.

Identification of Metabolites by LC-MS/MS.

Canagliflozin and its metabolites were initially detected by LC radioprofiling with subsequent structure elucidation using unit resolution multiple-stage mass spectrometric analyses. Product ions from multiple-stage mass analysis were used to elucidate the site of biotransformation based on mass shift of the ammonium adduct and its product ions from those derived from canagliflozin. Therefore, high resolution accurate mass measurement of canagliflozin by LTQ/Orbitrap was conducted to confirm assignment of its product ions from unit mass resolution. These results were used to bridge and facilitate the assignment of product ions from each metabolite.

The ammonium adducts, diagnostic product ions, biotransformation pathways and detection in species investigated of canagliflozin and its metabolites are tabulated in Table 7. The identity of a metabolite was confirmed by either co-chromatography with reference standard or by 1D- and 2D-NMR analysis. Details of the structural elucidation of canagliflozin and its metabolites by multiple-stage mass spectrometry analyses are described below. Mass spectra of unchanged drug, and major animal and human metabolites are shown in Figs. 8, 9 and 10.

The proposed structures of detected metabolites were used to postulate the in vivo metabolic pathways for canagliflozin in mice, rats, dogs and humans (Fig. 7).

Canagliflozin

The accurate full scan and product ion mass spectra of canagliflozin are shown in Fig. 8. Full scan mass analysis gave an ammonium adduct $[M+NH_4]^+$ instead of protonated molecule of canagliflozin at m/z 462 (462.17450, $C_{24}H_{29}O_5NFS$, 10.5 RDB, 0.00 ppm), which is commonly observed with electrospray ionization of neutral compound. Collision-induced dissociation of $[M+NH_4]^+$ at m/z 462 gave product ion at m/z 445 (445.14838, $C_{24}H_{26}O_5NFS$, 11.5 RDB, 0.97

ppm) from loss of NH₃, which further undergoes sequential loss of H₂O to form ions at *m/z* 427 (427.13745, C₂₄H₂₄O₄NFS, 12.5 RDB, 0.15 ppm), 409 (409.12717, C₂₄H₂₂O₃NFS, 13.5 RDB, 0.86 ppm), 391 (391.11655, C₂₄H₂₀O₂NFS, 14.5 RDB, 0.29 ppm) and 373 (373.10547, C₂₄H₁₈ONFS, 15.5 RDB, -0.59 ppm). Product ions at *m/z* 367 (367.11600, C₂₂H₂₀O₂FS, 12.5 RDB, -0.70 ppm), 349 (349.10559, C₂₂H₁₈OFS, 13.5 RDB, -0.29 ppm) and 325 (325.10562, C₂₀H₁₈OFS, 11.5 RDB, -0.22 ppm) were postulated to derive from cleavage of the 6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol moiety based on chemical formulae from accurate mass measurements (see insert structure). Two product ions at *m/z* 267 (267.12268, C₁₄H₁₉O₅, 5.5 RDB, -0.08 ppm) and 191 (191.03255, C₁₁H₈FS, 7.5 RDB, 0.13 ppm) from cleavage of bond linking benzylic carbon and thiophene moiety and bond linking benzylic carbon and 4-methylphenyl moiety, respectively, are useful in localization of site of biotransformation. The product ion at *m/z* 267 undergoes sequential losses of H₂O to form ions at *m/z* 249 (249.11197, C₁₄H₁₇O₄, 6.5 RDB, -0.66 ppm) and 231 (231.10150, C₁₄H₁₅O₃, 7.5 RDB, -0.31 ppm). Alternatively, the product ion at *m/z* 267 undergoes cleavage of the 6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol moiety to form ions at *m/z* 171 (171.08018, C₁₂H₁₁O, 7.5 RDB, -1.53 ppm) and 147 (147.08009, C₁₀H₁₁O, 5.5 RDB, -2.39 ppm).

Metabolite M1

The [M+NH₄]⁺ of M1 at *m/z* 654 was 192 Da higher than that of canagliflozin, which corresponded to addition of an oxygen atom and a glucuronide moiety to canagliflozin. This was supported by loss of 176 Da to form the [M+NH₄]⁺ of the aglycone of M1 at *m/z* 478. The diagnostic product ions at *m/z* 347, 323, and 191 localized the addition of the oxygen atom likely to the 1-ethyl-4-methylbenzene moiety of canagliflozin. The product ions at *m/z* 347 and 323 were speculated to correspond to addition of an oxygen atom and followed by loss of a water

molecule from product ion of canagliflozin at m/z 349 and 325, respectively. Hence, M1 was assigned the structure of a glucuronide conjugate of a hydroxylated metabolite of canagliflozin.

Metabolite M2

M2 had an identical ammonium adduct and product ions as the metabolite M1, which suggested that M2 was an isomer of metabolite M1. Thus, M2 was identified as another glucuronide conjugate of a hydroxylated metabolite of canagliflozin.

Metabolite M4

The ammonium adduct of M4 was 32 Da higher than that of canagliflozin, suggesting that M4 resulted from addition of 2 oxygen atoms. The addition of 32 Da to product ion of canagliflozin at m/z 325 and followed by sequential loss of a water molecule gave product ions of M4 at m/z 339 and 321, respectively. This together with the product ion at m/z 191 infers that the 2 additional oxygen atoms are localized to the 1-ethyl-4-methylbenzene moiety of canagliflozin.

Metabolite M5

The ammonium adduct of metabolite M5 displayed a higher mass shift of 176 Da from the corresponding ion of canagliflozin. This mass shift was consistent with a direct ether glucuronide conjugate of canagliflozin and was supported by detection of the ammonium adduct of the aglycone at m/z 462, which was identical to the ammonium adduct of canagliflozin. Also, the product ion mass spectra contained many of the diagnostic product ions of canagliflozin at m/z 445, 427, 409, 391, 373, 349, 325, 267 and 191 (Fig. 9A). NMR analysis of M5 isolated from human urine demonstrated that attachment of the glucuronide moiety was at the 2' of 2-hydroxymethyl-tetrahydropyrantriol moiety (Supplemental Fig. 2; Supplemental Table 1). The metabolite M5 was confirmed by its co-elution with reference synthetic standard and good agreement of their product ion mass spectra (data not shown).

Metabolite M6

M6 had an ammonium adduct at m/z 476 that was 14 Da higher than that of canagliflozin, which was consistent with addition of an oxygen atom and loss of 2 hydrogens. The product ion at m/z 267 from canagliflozin was shifted by 14 Da to form the product ion of M6 at m/z 281 which lost a water molecule to form m/z 263. These ions together with observation of identical unchanged product ions of canagliflozin at m/z 325, 191 and 147 suggested the site of biotransformation occurred on the 6-hydroxymethyl group of the 6-(hydroxymethyl)tetrahydro-2*H*-pyran-3,4,5-triol moiety. Therefore, M6 was assigned the structure of a carboxy metabolite and was confirmed by its co-elution with reference synthetic standard and good agreement of their product ion mass spectra (data not shown).

Metabolite M7

The full scan and product ion mass spectra of metabolite M7 were similar to the mass spectra of M5 (Fig. 9). Therefore, like M5, the metabolite M7 was assigned the structure of an isomeric ether glucuronide of canagliflozin. NMR analysis of M7 isolated from human urine demonstrated that attachment of the glucuronide moiety was at the 3' of 2-hydroxymethyl-tetrahydropyrantriol moiety (Supplemental Fig. 3; Supplemental Table 1). The metabolite M7 was confirmed by its co-elution with reference synthetic standard and good agreement of their product ion mass spectra (data not shown).

Metabolite M8

M8 displayed an ammonium adduct at m/z 478 that was 16 Da higher than that of canagliflozin and was consistent with addition of an oxygen atom. The product ion at m/z 323 was postulated to derive from addition of an oxygen atom to the product ion from canagliflozin at m/z 325 followed by loss of a water molecule (Fig. 10A). This ion together with the product ion at m/z 191 localized the likely addition of an oxygen atom to the 1-ethyl-4-methylbenzene moiety of

canagliflozin. As shown by NMR analysis of M8 isolated from rat methanolic feces extract, hydroxylation occurred at the methyl group of the 1-ethyl-4-methyl-benzene moiety of unchanged drug. Hence, M8 was assigned the structure of a hydroxylated metabolite of canagliflozin. The metabolite M8 was confirmed by its co-elution with reference synthetic standard and good agreement of their product ion mass spectra (data not shown).

Metabolite M9

The metabolite M9 was another hydroxylated metabolite of canagliflozin based on the identical ammonium adduct as M8, M18 and M19 at m/z 478. The observed identical product ion from canagliflozin at m/z 267 and the 16 Da higher mass shift of the ion at m/z 191 from canagliflozin to form the product ion at m/z 207 suggested the likely addition of an oxygen atom to (4-fluorophenyl)-thiophene moiety (Fig. 10B). NMR analysis of M9 isolated from mouse feces confirmed that hydroxylation occurred on the benzylic carbon linking methyl-phenyl and thiophene moieties of the unchanged drug (Supplemental Fig. 4; Supplemental Table 1). M9 was confirmed by its co-elution with reference synthetic standard and good agreement of their product ion mass spectra (data not shown). The hydroxylation of the prochiral benzylic carbon atom created a chiral center resulted in M9 consisted of diastereomers, however separation of the diastereomers or the chirality of M9 was not established.

Metabolite M10

M10 had similar full scan and product ion mass spectra as M8 and is thus likely to be an isomer of M8. Thus, M10 was assigned the structure of a hydroxylated metabolite of canagliflozin and with the oxygen atom likely to be added to the 1-ethyl-4-methylbenzene moiety of canagliflozin.

Metabolite M12

The ammonium adduct of M12 displayed a higher mass shift of 30 Da from canagliflozin, which was consistent with the addition of 2 oxygen atoms and loss of 2 hydrogens from canagliflozin. The product ions at m/z 349 and 325 from canagliflozin were observed to shift by 30 Da higher to form the product ions of M12 at m/z 379 and 355, respectively. The product ion at m/z 323 originated from addition of 30 Da to 2-(2,5-dimethylbenzyl)-5-(4-fluorophenyl)thiophene moiety of canagliflozin. Thus, M12 was assigned the structure from initial dihydroxylation and followed by further oxidation of 1 hydroxyl group to a carbonyl functionality.

Metabolite M13/M14

M13 and M14 had an ammonium adduct at m/z 654 that was 192 Da higher than that of canagliflozin and the mass shift of 192 Da corresponded to addition of an oxygen atom and a glucuronide moiety. This was supported by detection of the ammonium adduct of the aglycone at m/z 478, which was 16 Da higher than the corresponding ion from canagliflozin. The detection of the unchanged product ions from canagliflozin at m/z 267, 249, and 231 and the higher 16 Da mass shift of the m/z 207 (191 + 16) ion from canagliflozin points to oxidation of the 4-fluorophenyl-thiophene moiety. However, the exact site of glucuronidation could not be inferred from the product ion mass spectra. M13 and M14 were identified as *O*-glucuronides of a hydroxylated metabolite of canagliflozin.

Metabolite M15

M15 showed full scan and product ion mass spectra similar to those of the isomeric metabolite M14. The product ions from canagliflozin at m/z 267, 249 and 231 were unchanged in M15, and together with 16 Da higher mass shift of the ion at m/z 191 from canagliflozin to give the product ion at m/z 207, suggested the addition of the oxygen atom to (4-fluorophenyl)-thiophene moiety.

Therefore, M15 is another ether glucuronide of a hydroxylated metabolite of canagliflozin, but the site of glucuronidation could not be ascertained.

Metabolite M16

M16 had an identical ammonium adduct at m/z 654 as M14 and M15, which suggested that M16 was an isomer. The product ion at m/z 207 was speculated to derive from 16 Da higher mass shift of the product ion from canagliflozin at m/z 191 and therefore, the addition of an oxygen atom was localized to (4-fluorophenyl)-thiophene moiety. Thus M16 was assigned as another isomeric glucuronide conjugate of a hydroxylated metabolite with an uncertain site of glucuronidation.

Metabolite M17

The ammonium adduct of M17 was detected at m/z 638, which was identical to that of M5 and M7. The observed ammonium adduct of the aglycone at m/z 462 together with the diagnostic product ions at m/z 567 ($391 + 176$), 549 ($379 + 176$), 531 ($549 - H_2O$), 462 (ammonium adduct parent drug), 427, 409, 391, 373, 349, 325, 267, 231 and 191 from collision-induced dissociation suggested that M17 was an isomeric ether glucuronide conjugate of canagliflozin. The site of glucuronidation cannot be established from MS data.

Metabolite M18

The ammonium adduct of metabolite M18 was observed at m/z 478 and the 16 Da higher mass shift from canagliflozin was consistent with addition of an oxygen atom. The unchanged product ion from canagliflozin at m/z 267 together with 16 Da higher mass shift of the ion at m/z 191 from canagliflozin to form product ion at m/z 207 suggested the addition of an oxygen atom to the (4-fluorophenyl)-thiophene moiety. M18 was therefore assigned the structure of a hydroxylated metabolite and with site of hydroxylation localized to (4-fluorophenyl)-thiophene moiety.

Metabolite M19

M19 showed an ammonium adduct at m/z 478 that was 16 Da higher than that of canagliflozin and was consistent with addition of an oxygen atom. The product ion at m/z 323 can be explained by a water loss from the oxidized canagliflozin product ion at m/z 325. This ion together with the unchanged product ion at m/z 191, indicating that the 2-(4-fluorophenyl)methylthiophene moiety is unchanged, and points to oxidation of the 1-ethyl-4-methylbenzene moiety of canagliflozin. Hence, M19 was assigned the structure of a hydroxylated metabolite of canagliflozin and probably an isomer of M8.

In Vitro Pharmacological Activity.

Metabolites M5 and M7 were separately tested for potential inhibitory activity on substrate uptake by human SGLT2 expressed in CHO K1 cells. Canagliflozin was included as a positive control in each assay. The IC_{50} values for canagliflozin and M5 were 1.3 nM and 1014 nM, respectively, and for canagliflozin and M7, these values were 7.3 nM and 5900 nM, respectively. M5 and M7 are each 800-fold less potent than canagliflozin and are considered pharmacologically inactive.

Discussion

In this study, the excretion and biotransformation of canagliflozin after a single oral administration of [^{14}C]canagliflozin was investigated in mice, rats, dogs, and humans. Canagliflozin was well tolerated at the doses used in the metabolism and excretion studies in mice, rats, dogs, and at the dose given to normal healthy subjects during the mass-balance study. Mass-balance for orally administered [^{14}C]canagliflozin was achieved based on a range of 93 to 99% recovery of total radioactivity from excreta of intact animals and humans (Beumer et al., 2006). In human subjects, the proportion of TR eliminated into urine (33%) surpassed that of animal species (2 to 7%). The majority (ie, 89-94%) of the administered radioactive dose in

animals was excreted in feces, and a substantial amount of TR (60%) in humans was recovered in feces.

Liquid chromatography with radioactivity detection and MS/MS analysis of fecal, urine and bile samples indicated that canagliflozin was converted to a number of metabolites. The proposed in vivo biotransformation pathways for canagliflozin are shown in Fig. 7. Oxidative metabolism and glucuronidation are the proposed in vivo metabolic pathways of canagliflozin in animal species and humans.

Unchanged drug was the major circulating component in all species investigated. The *O*-glucuronides M5 and M7 were the major circulatory metabolites in human, and M9, an oxidative product was a minor metabolite. In comparison, there was low abundance of M5, M7 and M9 in mouse plasma, and no circulatory metabolites were detected in rat and dog. The absence of or low abundance of circulatory metabolites in animal species is consistent with their elimination primarily by the biliary/fecal route.

Canagliflozin is extensively metabolized in animals. Metabolites and unchanged drug represented 53 to 88% and ~4 to 33%, respectively, of the total radioactive dose recovered in mouse, rat, and dog feces. Oxidative metabolism as the primary mode of biotransformation in animal species is supported by the high abundance of hydroxylated metabolites M8 and M9 in excreta, where together they accounted for 41 to 70% of the administered radioactive dose. The other metabolites were those formed by oxidation (M4, M6, and M10), and a combination of oxidation followed by glucuronidation (M1 and M2). The presence of M5 and M7 in mouse feces, and M7 in dog feces, indicates that direct *O*-glucuronidation of canagliflozin occurs in animals. The minor metabolites M1 and M2 are postulated to be *O*-glucuronide isomers of M8.

In humans, canagliflozin is less extensively metabolized than in animal species. M5, M7 and M9 were the only human metabolites identified, and these were detected in at least 1 animal species used in canagliflozin safety assessments. The presence of M5 and M7 as major metabolites in plasma and urine demonstrates that *O*-glucuronidation is the primary biotransformation pathway in humans. Unlike animal species, oxidative metabolism is considered to be a minor metabolic pathway in humans because of the low abundance of M9 in feces. Results from a reaction phenotyping study with recombinant human CYP or UGT enzymes suggested that CYP3A4 metabolizes canagliflozin to M9; and UGT1A9 and UGT2B4 metabolizes canagliflozin to M7 and M5, respectively (unpublished results).

Studies in BDC mice and rats showed that a large portion of radioactivity from administered [¹⁴C]canagliflozin is excreted into bile, amounting to approximately 50% of the dose in each species. M7 was the main metabolite found in mouse and rat bile. Other metabolites detected in rat bile included direct *O*-glucuronide conjugates (M5, M5B), minor oxidative metabolites (M12, M18 and M19), and oxidative metabolites that further underwent glucuronidation (M1, M13, M14, M15, M16). Results from the analysis of bile samples treated with β-glucuronidase substantiated that M1, M5, M5B, M7, M13, M14 were glucuronide conjugates. Based on the hydrolysis experiment and mass spectrometric analysis of bile samples, it was confirmed that M13, M14, and M1 are glucuronide conjugates of M8, M18, and M8 respectively. However, the position of glucuronidation on M8 or M18 could not be confirmed.

The high abundance of canagliflozin in feces from male mice (33%) and humans (39%) is consistent with the aglycone arising from enzymatic hydrolysis of glucuronide metabolites in the gastrointestinal tract. The primary source of fecal canagliflozin appears to be M7 since it represented 37% of the dose excreted in bile of male mice, but amounted to only 6% of the dose

in feces of intact male mice. Similarly, the percentage of M7 in human feces was low (2%). Hydrolysis of glucuronides in the gastrointestinal tract was supported by an experiment with mouse and human fecal aqueous homogenates. When M5 and M7 were incubated in vitro with the fecal preparations, they were rapidly hydrolyzed to canagliflozin, presumably by gut microflora glucuronidases (unpublished results).

The pooled plasma metabolite profiles for different species allow for direct comparison of the extent of systemic exposures to drug-related components at well-tolerated dose levels. After [¹⁴C]canagliflozin was orally administered, the percentage of sample radioactivity representing unchanged drug was 94% to 98% in 0 to 24 h-pooled plasma samples of animal species. In human plasma samples, the percentage of sample radioactivity attributed to canagliflozin was 45% to 66% at 1.5 to 12 h, and 99% at 24 h. Components accounting for the remainder of sample radioactivity during the 1.5-12 h period were metabolites M7 (16% to 29%), M5 (2% to 30%), and a M9 (2% to 4%). Among animal species, M7 and M9 were detected only in plasma from mice (about 2% to 3%). However, after repeated dosing with 100 mg/kg canagliflozin in chronic mouse, rat, and dog toxicology studies, M5 and M7 were found at quantifiable levels in plasma samples analyzed by LC-MS/MS. Moreover, biliary excretion studies in mouse and rat confirm substantial exposure of liver to M5 and M7, the primary organ for the metabolism of canagliflozin.

M5 and M7 have been excluded from safety testing because they are 800-fold less potent as SGLT2 inhibitors compared to canagliflozin and are considered pharmacologically inactive. The high percentage excretion of M5 and M7 in human urine is consistent with rapid elimination from the body due to their high water solubility (≥ 50 mg/mL), whereas canagliflozin is practically insoluble in water (~ 0.150 mg/mL).

Nonclinical safety testing of human metabolites is required when circulating levels are significantly greater than the maximum exposure seen in the nonclinical toxicity studies. This rule applies when exposure of the metabolite in plasma is greater than 10% of total drug-related exposure. Some metabolites, such as *O*-glucuronides, are excluded from safety testing because they are generally pharmacologically inactive and chemically nonreactive in nature (Gao H et al., 2013). As discussed above, M5 and M7 met these criteria and were therefore excluded from safety testing.

In conclusion, canagliflozin elimination in animals and humans is through biotransformation pathways of oxidation and *O*-glucuronidation. In animal species, oxidative metabolites of canagliflozin account for the majority of drug-related material, and these are eliminated mainly into feces via biliary excretion. In humans, the major circulatory metabolites M5 and M7 are formed by direct *O*-glucuronidation of canagliflozin and are mainly excreted in urine. However, elimination of M5 and M7 in feces may be underestimated due to enzyme-mediated hydrolysis of glucuronides back to parent drug, presumably by microflora in the gastrointestinal tract. All human metabolites were detected in at least one nonclinical species used in the safety assessments of canagliflozin. Although the *O*-glucuronides M5 and M7 are major human circulating metabolites, their pharmacological inactivity is consistent with the scientific consensus that such conjugates pose minimal or no safety risk.

Acknowledgments

The authors are grateful to Dr. Gerry Gendimenico (Janssen Pharmaceutical & Research Development, LLC) for providing editorial assistance with the manuscript. The authors thank Dr. Geert Mannens (Janssen Pharmaceutical Research & Development) for evaluation of radiation exposure, Dr. Yong Gong (Janssen Pharmaceutical & Research Development, LLC),

Dr. Marteen Vliegen, and Dr. Walter Filliers (both of Janssen Pharmaceutical Research & Development) for synthesis and purification of reference metabolites and, Dr. Yin Liang (Janssen Pharmaceutical & Research Development, LLC) for testing the pharmacological activity of canagliflozin and its two glucuronide conjugates.

Authorship Contributions

Participated in research design: Mamidi, Cuyckens, Scheers, Silva, Sha, Kelley, Devineni, Johnson, Lim

Conducted experiments: Chen, Kalamaridis, Lin, Sha

Contributed new reagents or analytic tools: Lin, Lim

Performed data analysis: Mamidi, Cuyckens, Chen, Scheers, Kalamaridis, Lim

Wrote or contributed to the writing of the manuscript: Mamidi, Cuyckens, Scheers, Evans, Kelley, Devineni, Johnson, Lim

References

Beumer JH, Beijnen JH, and Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. *Clin Pharmacokinet* 45:33-58.

Chen L, Magliano DJ, and Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. *Nat Rev Endocrinol* 8:228-236.

Cuyckens F, Koppen V, Kembuegler R, and Leclercq L (2008) Improved liquid chromatography-online radioactivity detection for metabolite profiling. *J Chromatogr A* 1029:128-135.

Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, and Rothenberg PL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. *J Clin Pharmacol* 53:601-610.

Gao H, Jacobs A, White RE, Booth BP, and Obach RS (2013) Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests? *AAPS J* 15:970-973/973.

Hamilton RA, Garnett WR, and Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. *Clin Pharmacol Ther* 29:408-413.

Hardman TC and Dubrey SW (2011) Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. *Diabetes Ther* 2:133-145.

Institute of Laboratory Animal Resources (1996) *Guide for the Care and Use of Laboratory Animals* 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.

Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, and Demarest K (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. *PLoS One* 7:e30555.

Lim HK, Chen J, Sensenhauser C, Cook K, and Subrahmanyam V (2007) Metabolite identification by data-dependent accurate mass spectrometric analysis at resolving power of 60,000 in external mass calibration mode using LTQ/Orbitrap. *Rapid Commun Mass Spectrom* 21:1821-1832.

Lim HK, Chen J, Sensenhauser C, Cook K, Preston R, Thomas T, Shook B, Jackson PF, Rassnick S, Rhodes K, GoPaul V, Salter R, Silva J, and Evans DC (2011) Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent dual adenosine A(2A/A(1)) antagonist by minimizing bioactivation to an iminium ion reactive intermediate. *Chem Res Toxicol* 24:1012-1030.

Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, Nakayama K, and Tsuda-Tsukimoto M (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. *J Med Chem* 53:6355-6360.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, and Canovatchel W (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. *Diabetes Care* 35:1232-1238.

Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, and Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. *Diabetes Obes Metab* 13:669-672.

Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, and Cowie CC (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. *Diabetes Care* 36:2271-2279.

Verbruggen A, Coenen HH, Deverre JR, Guilloteau D, Langstrom B, Salvadori PA, and Halldin C (2008) Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. *Eur J Nucl Med Mol Imaging* 35:2144-2151.

Wright EM, Hirayama BA, and Loo DF (2007) Active sugar transport in health and disease. *J Intern Med* 261:32-43.

Figure Legends

Fig. 1. Structure of [¹⁴C]canagliflozin with position of ¹⁴C label (*)

Fig. 2. LC-radiochromatograms of canagliflozin and metabolites in plasma of male mice (A) and humans (B). Administered doses are shown in Table 3.

Fig. 3. Concentrations of total radioactivity (TR), canagliflozin and its metabolites in pooled human plasma samples after a single oral administration of 188 mg of [¹⁴C]canagliflozin to healthy human subjects. Percentages of unchanged drug and metabolites in plasma samples from the mass-balance study were converted to concentrations (ng-base eq./mL) using a specific activity of 7.72 KBq/mg (463.2 dpm/μg). TR in plasma was quantified by LSC.

Fig. 4. LC-radiochromatograms of canagliflozin and metabolites in urine of female mice (A), and in male rats (B), dogs (C), and humans (D). Administered doses are shown in Table 3.

Fig. 5. LC-radiochromatograms of canagliflozin and its metabolites in feces of female mice (A), and in male rats (B), dogs (C), and humans (D). Administered doses are shown in Table 3.

Fig. 6. LC-radiochromatograms of canagliflozin and metabolites in untreated rat bile (A) or after in vitro treatment of rat bile with β-glucuronidase/arylsulfatase (B). The administered dose is shown in Table 6.

Fig. 7. Proposed in vivo metabolic pathways for canagliflozin in mice, rats, dogs, and humans

Fig. 8. Accurate mass full scan (A) and product ion mass spectra (B) of canagliflozin

Fig. 9. Product ion mass spectra of M5 (A) and M7 (B)

Fig. 10. Product ion mass spectra of M8 (A) and M9 (B)

Table 1: Percentage of radioactive dose recovery in mice, rats, dogs, and humans

Species	Sex	No. of Subjects	Dose	Collection Interval (h)	%Radioactive Dose			
					Urine	Bile	Feces	Total
Intact Mouse	Male	4	100 mg/kg	96	5.81	N.A.	91.8	97.8
	Female	4	100 mg/kg	96	6.46	N.A.	91.7	98.3
BDC Mouse	Male	5	100 mg/kg	24	N.A.	49.1	N.A.	N.A.
Intact Rat	Male	4	3 mg/kg	120	4.0	N.A.	88.5	96.9
	Female	4	3 mg/kg	120	5.14	N.A.	89.9	98.4
BDC Rat	Male		3 mg/kg	24	3.71	52.2	22.4	78.3
Dog	Male	3	4 mg/kg	144	1.9	N.A.	93.6	99.1
Human	Male	6	188 mg	168	32.5	N.A.	60.4	92.9

N.A., not applicable

Table 2: Mean pharmacokinetic parameters of total radioactivity in mice, rats, dogs and humans

Species	Sex	No. of Subjects	Dose	C _{max} (µg/mL)	T _{max} (h)	AUC _{0-∞} (µg·h/mL)
Mouse	Male	4	100 mg/kg	29.9	7	451
	Female	4	100 mg/kg	34.79	4	498
Rat	Male	4	3 mg/kg	1.21	8	17.7
	Female	4	3 mg/kg	0.933	4	12.1
Dog	Male	3	4 mg/kg	5.49	1	87.3
Human	Male	6	188 mg	3.74	2 ^a	28.2

^a Median value

Table 3: Relative distribution of metabolites in pooled plasma from mice, rats, dogs, and humans after oral administration of [¹⁴C]canagliflozin

Metabolite Identification	%Sample Radioactivity ^a					
	Mouse		Rat		Dog	Human
	100 mg/kg		3 mg/kg		4 mg/kg	188 mg
	Male	Female	Male	Female	Male	Male
Canagliflozin	94.2	93.9	98.2	98.6	98.7	61.8
M5	N.D.	N.D.	N.D.	N.D.	N.D.	19.2
M7	2.6	1.6	N.D.	N.D.	N.D.	13.6
M9	1.6	2.2	N.D.	N.D.	N.D.	3.1
Total	98.4	97.7	98.2	98.6	98.7	97.7

N.D., not detected

^aPlasma samples pooled over 0 to 24 h

Table 4: Systemic exposure to total radioactivity, canagliflozin and its metabolites in plasma of human subjects following oral administration of [¹⁴C]canagliflozin

Analyte	AUC (ng-eq.hr/mL) ^a	% Total Radioactivity
Total Radioactivity (¹⁴ C)	28195 ^b	100
Canagliflozin	16892	59.9
M5	5207	18.5
M7	4385	15.6
M9	678	2.4

^a Calculated from radio-HPLC analysis of plasma samples pooled at each time point

^b Mean of AUC values from 6 healthy male subjects

Table 5: Relative distribution of metabolites in urine from mice, rats, dogs, and humans after oral administration of [¹⁴C]canagliflozin

Metabolite Identification	%Dose ^a					
	Mouse		Rat		Dog	Human
	100 mg/kg		3 mg/kg		4 mg/kg	188 mg
	Male	Female	Male	Female	Male	Male
Canagliflozin	0.3	0.2	0.2	0.3	0.3	N.D.
M1	0.7	0.1	N.D.	N.D.	N.D.	N.D.
M2	0.3	N.D.	N.D.	N.D.	N.D.	N.D.
M4	N.D.	0.4	N.D.	N.D.	0.4	N.D.
M5	N.D.	0.1	N.D.	N.D.	N.D.	13.7
M6	N.D.	N.D.	0.9	0.4	N.D.	N.D.
M7	1.3	1.1	N.D.	N.D.	N.D.	18.2
M8	0.2	1.0	2.7	4.1	0.8	N.D.
M9	2.3	3.3	0.4	0.6	0.5	N.D.
Total	5.1	6.2	4.0	5.3	2.0	31.9

N.D., not detected

^aUrine samples pooled over 0 to 48 h

Table 6: Relative distribution of metabolites in feces and bile from mice, rats, dogs, and humans after oral administration of [¹⁴C]canagliflozin

Metabolite Identification	% Dose							
	Feces ^a				Bile ^b			
	Mouse		Rat		Dog	Human	Mouse	Rat
	100 mg/kg		3 mg/kg		4 mg/kg	188 mg	100 mg/kg	3 mg/kg
	Male	Female	Male	Female	Male	Male	Male	Male
Canagliflozin	32.5	10.1	3.5	5.3	11.1	38.7	4.4	2.17
M1	N.D.	N.D.	5.5	18	N.D.	N.D.	MS ^c	2.41
M2	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	MS	N.D.
M4	2.7	9.3	N.D.	N.D.	11.2	N.D.	N.D.	N.D.
M5	0.8	2.4	N.D.	N.D.	N.D.	N.D.	N.D.	4.01
M5B	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	2.13
M6	1.8	3.7	10.1	7.9	N.D.	N.D.	N.D.	5.93
M7	6.4	14	N.D.	N.D.	7.1	2.3	36.9	12.26
M8	13.6	17.3	51.9	58.8	41.8	N.D.	6.9	7.12
M9	27.6	29	17.6	2.1	22.5	7.6	N.D.	N.D.
M10	N.D.	N.D.	2.6	1.4	N.D.	N.D.	N.D.	N.D.
M12	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	1.52
M13/M14	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	1.56
M15	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	2.69
M16	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	1.27
M17	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	0.82
M18	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	1.93
M19	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	1.55
Total	85.4	85.8	91.2	93.5	93.7	48.6	48.2	47.37

N.D., not detected

^a Feces samples pooled over 0 to 48 h for mice, rats, and humans, and 0 to 72 h for dogs

^b Collection interval of 0 to 24 h

^c MS indicates the metabolite was only observed by mass spectrometry

Table 7: Mass spectral analysis of canagliflozin metabolites in mice, rats, dogs and humans

Metabolite	[M + H] ⁺	Diagnostic product ions ^a	Biotransformation Pathways	Species
Canagliflozin	462	445, 427, 409, 391, 373, 349, 325, 267, 191, 147	-	-
M1	654	619, 601, 583, 547, 478, 443 , 425, 407, 389, 347, 323, 191	Oxidation, glucuronidation	Mouse, rat
M2	654	619, 601, 583, 547, 478, 443 , 425, 407, 389, 347, 323, 191	Oxidation, glucuronidation	Mouse
M4	494	459, 441, 423, 405, 387, 369, 339, 321, 191	Oxidation	Mouse, dog
M5	638	603, 585, 567, 549, 531, 507, 487, 462, 445 , 427, 409, 391, 373, 349, 325, 267, 191	Glucuronidation	Mouse, rat, dog, human
M6	476	459, 441, 423, 405, 387, 325, 281, 263, 191, 147	Alcohol oxidation	Mouse, rat
M7	638	603, 585, 567, 549, 531, 507, 487, 462, 445 , 427, 409, 391, 373, 349, 325, 267, 191	Glucuronidation	Mouse, rat, dog, human
M8	478	460, 443, 425, 407, 389, 347, 323, 191	Hydroxylation	Mouse, rat, dog
M9	478	461, 443, 425, 407, 389, 365, 341, 267, 207	Hydroxylation	Mouse, rat, dog, human
M10	478	460, 443, 425, 407, 389, 347, 283, 191	Oxidation	Rat
M12	492	475, 457, 439, 421, 403, 379, 355, 337, 323	Oxidation	Rat
M14	654	619, 601, 583, 565, 547, 523, 478, 461, 443, 425, 407, 389, 365, 341, 231, 207	Oxidation, glucuronidation	Rat
M15	654	601, 583, 565, 547, 523, 461, 425, 407, 389, 383, 365, 341, 267, 231, 207	Oxidation, glucuronidation	Rat
M16	654	461, 443, 425, 407, 376, 365, 341, 207	Oxidation, glucuronidation	Rat
M17	638	549, 531, 462, 427, 409, 391, 373, 349, 325, 267, 231, 191	Glucuronidation	Rat
M18	478	461, 443, 425, 407, 389, 383, 365, 341, 267, 249, 231, 207	Oxidation	Rat
M19	478	461, 443, 425, 407, 365, 353, 341, 207	Oxidation	Rat

^a Diagnostic fragments shown in bold font

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

